- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7403
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dopamine agonist resistant prolactinomas: any alternative medical treatment? ; volume:23 ; number:1 ; day:14 ; month:9 ; year:2019 ; pages:27-37 ; date:2.2020
Pituitary ; 23, Heft 1 (14.9.2019), 27-37, 2.2020
- Creator
-
Souteiro, P.
Karavitaki, N.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11102-019-00987-3
- URN
-
urn:nbn:de:101:1-2020041815185931120634
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Souteiro, P.
- Karavitaki, N.
- SpringerLink (Online service)
Other Objects (12)
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas